动态68Ga-PSMA-11 PET/CT用于局限性肾脏肿块初级评估的前瞻性研究
该前瞻性病例系列纳入27例新诊断肾脏肿块拟手术患者,术前行动态68Ga-PSMA-11 PET/CT,以手术病理为标准,比较良恶性病变的示踪剂摄取、动力学参数及PSMA表达。结果显示恶性病变SUVmean、SUVmax更高,洗脱系数K2更低,PSMA染色阳性率更高,提示动态PSMA PET/CT有潜力用于局限性肾脏肿块评估。
要点
- 恶性肾脏肿块SUVmean和SUVmax均显著高于良性病变。
- 恶性病变洗脱系数K2显著低于良性病变。
- 恶性病变PSMA染色阳性率显著高于良性病变。
核心结论
- 动态68Ga-PSMA-11 PET/CT在局限性肾脏肿块中显示出与病理良恶性相关的摄取和动力学差异,支持进一步评估其作为评估工具的潜力。
研究设计与样本
- 前瞻性病例系列,纳入27例新诊断肾脏肿块并转诊手术的患者,术前按标准化方案行动态68Ga-PSMA-11 PET/CT,以最终手术组织学为标准参考。
主要发现
- 29个强化肾脏肿块中24个(83%)为恶性病变。
- 良性与恶性病变的中位SUVmean分别为2.3(IQR 2.2-2.7)和6.8(IQR 4.2-10.1),P=0.009。
- 良性与恶性病变的中位SUVmax分别为3.8(IQR 3.3-4.5)和9.4(IQR 5.4-15.8),P=0.015。
- 恶性病变的中位洗脱系数K2显著低于良性病变(0.17 vs. 0.70,P=0.02)。
- 24个恶性病变中20个PSMA染色阳性,5个良性病变中2个PSMA染色阳性(P=0.04)。
临床怎么用
- 在局限性肾脏肿块术前评估中,可考虑动态68Ga-PSMA-11 PET/CT提供良恶性鉴别参考,但尚属研究性应用。
局限性
- 本研究为试点性小样本病例系列,结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The potential role of prostate-specific membrane antigen (PSMA) PET/CT in non-prostate cancer tumors has shown promising results. We examined the performance of dynamic 68Ga-PSMA-11 PET/CT (DPSMA) for the evaluation of localized renal mass. Methods: A prospective case series of patients with a newly diagnosed renal mass who were referred for surgery was examined. DPSMA was performed in a standardized manner before surgery. The final surgical histology served as the standard of reference. PSMA expression in the tumor vasculature was assessed and staining intensity was scored. Tracer uptake and PSMA expression were compared between benign and malignant tissue. Results: Of 29 enhancing renal masses evaluated in 27 patients, 24 (83%) were malignant lesions. The median SUVmean of benign and malignant lesions was 2.3 (interquartile range [IQR], 2.2-2.7) and 6.8 (IQR, 4.2-10.1), respectively (P = 0.009). Median SUVmax of benign and malignant lesions was 3.8 (IQR, 3.3-4.5) and 9.4 (IQR, 5.4-15.8), respectively (P = 0.015). The median washout coefficient (K2) was significantly lower in malignant lesions than in benign lesions (0.17 vs. 0.70, P = 0.02). Positive PSMA staining was found in 20 of 24 malignant lesions and in 2 of 5 benign lesions (P = 0.04). Conclusion: This pilot study demonstrated DPSMA uptake and kinetics in localized renal masses. Increased 68Ga-PSMA-11 tracer uptake and intratumoral retention correlate with PSMA expression in malignant renal tumors compared with benign renal masses, supporting further assessment of DPSMA as a potential tool for evaluating localized renal masses.
引用
- Golan S, Aviv T, Groshar D, et al. Dynamic 68Ga-PSMA-11 PET/CT for the Primary Evaluation of Localized Renal Mass: A Prospective Study. J Nucl Med. 2020. PMID: 33097628. doi:10.2967/jnumed.120.251272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。